Skip to main content

Table 1 Expression of the five candidate genes in cell lines from different cancer types

From: Correlation of gene expression and associated mutation profiles of APOBEC3A, APOBEC3B, REV1, UNG, and FHIT with chemosensitivity of cancer cell lines to drug treatment

Cancer type

n

APOBEC3A

APOBEC3B

UNG

REV1

FHIT

Range

Mean ± SD

Range

Mean ± SD

Range

Mean ± SD

Range

Mean ± SD

Range

Mean ± SD

ALL

2

3.40–3.75

3.58 ± 0.25

3.72–9.33

6.53 ± 3.97

10.04–10.56

10.3 ± 0.37

7.52–7.56

7.54 ± 0.03

4.68–7.33

6.01 ± 1.87

BLADDER

27

3.49–6.87

4.11 ± 0.74

3.60–11.51

9.59 ± 1.64

7.86–10.93

9.7 ± 0.81

5.86–8.21

7.01 ± 0.50

4.27–7.10

5.14 ± 0.70

BREAST

59

3.11–6.18

3.88 ± 0.47

3.13–11.28

8.78 ± 2.07

7.00–11.16

9.62 ± 0.82

5.89–8.31

6.98 ± 0.40

4.29–7.26

5.66 ± 0.82

CESC

22

3.14–4.81

3.79 ± 0.33

3.29–10.98

8.87 ± 2.15

8.28–10.39

9.62 ± 0.63

6.45–8.1

7.09 ± 0.45

4.29–7.73

5.87 ± 1.1

CLLE

78

3.29–6.63

3.87 ± 0.46

3.06–11.46

8.01 ± 2.39

7.37–11.50

9.7 ± 0.72

6.53–8.18

7.4 ± 0.36

4.46–10.24

6.59 ± 1.51

COAD/READ

62

3.22–4.54

3.81 ± 0.33

3.02–11.91

8.70 ± 2.30

7.67–10.97

9.75 ± 0.69

6.23–7.76

7.07 ± 0.29

4.30–7.81

6.05 ± 0.89

DA

2

3.36–3.37

3.36 ± 0.01

3.41–3.56

3.49 ± 0.11

9.36–9.95

9.66 ± 0.42

6.97–7.19

7.08 ± 0.16

4.75–4.96

4.85 ± 0.15

EC

26

3.34–5.21

3.90 ± 0.46

3.03–11.81

8.80 ± 2.39

8.51–10.64

9.69 ± 0.55

6.19–7.79

7.06 ± 0.38

4.49–8.34

5.29 ± 0.90

GLIOMA

79

3.27–4.44

3.76 ± 0.25

3.07–11.45

8.42 ± 2.71

7.82–11.09

9.34 ± 0.64

6.32–8.03

7.00 ± 0.34

4.08–7.33

5.13 ± 0.63

HNSC

33

3.34–11.29

4.93 ± 1.86

6.51–11.66

9.54 ± 1.27

7.82–10.35

9.01 ± 0.68

6.25–8.18

7.24 ± 0.45

4.26–6.06

4.85 ± 0.34

LAML

5

3.53–4.74

3.96 ± 0.47

8.14–10.67

9.44 ± 1.06

8.35–10.43

9.67 ± 0.82

7.22–7.69

7.47 ± 0.21

5.80–7.53

6.67 ± 0.80

LCML

1

6.20

6.20

12.56

12.56

9.79

9.79

6.54

6.54

7.69

7.69

LIHC

34

3.34–4.64

3.82 ± 0.3

3.34–12.42

8.39 ± 2.62

7.82–10.72

9.55 ± 0.67

6.07–8.02

6.88 ± 0.39

4.26–7.48

5.33 ± 0.74

MATBCL

60

3.36–5.15

3.84 ± 0.34

3.31–11.76

7.09 ± 2.68

5.81–10.69

9.33 ± 1.1

6.45–8.05

7.27 ± 0.44

4.34–10.67

6.35 ± 1.38

MB

2

3.48–3.83

3.65 ± 0.25

3.48–5.86

4.67 ± 1.68

7.69–9.75

8.72 ± 1.45

6.77–6.94

6.85 ± 0.12

6.00–7.68

6.84 ± 1.19

MEL

59

3.45–4.35

3.87 ± 0.21

3.47–11.81

9.81 ± 1.52

7.32–10.51

9.12 ± 0.62

6.41–7.91

6.91 ± 0.3

4.34–7.67

5.55 ± 0.78

MEN

3

3.65–4.05

3.85 ± 0.20

8.78–9.64

9.08 ± 0.48

8.69–9.72

9.15 ± 0.53

6.47–6.93

6.76 ± 0.25

4.84–5.96

5.25 ± 0.62

MESO

2

3.80–3.95

3.88 ± 0.11

9.92–11.05

10.48 ± 0.79

9.32–9.58

9.45 ± 0.19

6.61–6.8

6.71 ± 0.14

4.18–5.80

4.99 ± 1.15

MGCT

3

3.37–3.62

3.53 ± 0.14

7.19–9.23

8.28 ± 1.03

7.33–8.09

7.77 ± 0.40

6.40–6.73

6.60 ± 0.17

4.73–5.86

5.27 ± 0.57

MM

28

3.46–5.61

4.12 ± 0.48

2.96–12.09

9.52 ± 2.54

7.10–10.85

9.42 ± 0.91

5.83–7.31

6.68 ± 0.36

4.99–8.74

6.96 ± 1.00

NSCLC

186

3.06–7.82

3.79 ± 0.52

3.04–11.92

7.98 ± 2.59

7.85–11.31

9.67 ± 0.64

5.98–8.28

7.08 ± 0.45

4.14–8.11

5.43 ± 0.80

OVARIAN

51

3.31–4.46

3.72 ± 0.24

3.09–10.98

8.06 ± 2.3

7.32–10.71

9.35 ± 0.72

6.29–7.99

7.00 ± 0.32

4.26–8.38

5.79 ± 0.97

PAAD

44

3.28–6.13

3.89 ± 0.50

3.10–11.66

8.95 ± 2.31

7.50–10.95

9.54 ± 0.8

6.48–8.42

7.19 ± 0.36

4.43–7.44

5.34 ± 0.72

PNET

3

3.21–3.59

3.45 ± 0.21

2.94–3.50

3.21 ± 0.28

9.16–10.09

9.54 ± 0.49

6.57–7.58

7.06 ± 0.51

4.43–6.97

5.58 ± 1.29

PRAD

7

3.58–4.07

3.81 ± 0.19

3.33–9.99

8.10 ± 2.18

9.49–11.20

10.15 ± 0.67

6.48–7.65

6.98 ± 0.43

5.04–7.38

5.94 ± 1.01

RCC

36

3.23–4.17

3.70 ± 0.22

3.17–11.25

8.87 ± 1.97

7.70–9.98

9.18 ± 0.51

6.52–7.59

6.96 ± 0.25

4.57–7.05

5.7 ± 0.73

SAR

43

3.38–4.29

3.74 ± 0.23

3.15–11.24

8.37 ± 2.37

7.57–10.73

9.26 ± 0.79

6.48–7.95

7.03 ± 0.39

4.14–6.36

4.87 ± 0.49

SCLC

7

3.01–4.11

3.67 ± 0.39

3.28–11.28

7.38 ± 3.16

9.54–10.60

10.10 ± 0.45

6.88–8.02

7.49 ± 0.41

5.07–6.6

5.71 ± 0.55

STAD

38

3.16–4.58

3.72 ± 0.27

3.21–11.68

7.88 ± 2.68

8.51–10.38

9.53 ± 0.52

5.97–7.75

7.01 ± 0.44

4.35–7.81

5.62 ± 0.9

THCA

13

3.37–4.28

3.66 ± 0.22

3.87–10.97

8.57 ± 2.14

8.07–10.31

9.21 ± 0.62

6.32–7.67

6.94 ± 0.36

4.34–7.63

5.49 ± 0.98

UCEC

6

3.40–4.05

3.66 ± 0.26

3.81–10.99

8.84 ± 2.63

9.36–10.14

9.82 ± 0.32

6.18–7.28

6.78 ± 0.45

4.53–8.11

5.82 ± 1.32

MISC

15

3.36–6.68

4.01 ± 0.80

4.50–11.28

8.83 ± 1.80

7.18–10.42

9.11 ± 1.07

6.47–8.38

7.28 ± 0.53

4.17–6.90

5.26 ± 0.74

Pan-cancer

1036

3.23–8.48

3.89 ± 0.61

3.02–12.42

8.43 ± 2.43

7.00–11.50

9.41 ± 0.78

5.83–8.18

7.05 ± 0.42

4.14–10.67

5.74 ± 1.16

  1. n number of cell lines for each cancer type with available Affymetrix U133 2.0 plus microarray expression data, SD standard deviation, ALL acute lymphocytic leukemia, BLADDER bladder cancer, BREAST breast cancer, CESC cervical squamous cell carcinoma and endocervical adenocarcinoma, CLLE chronic lymphocytic leukemia, COAD/READ colon adenocarcinoma and rectum adenocarcinoma, DA duodenal adenocarcinoma, EC esophageal cancer, GLIOMA glioma brain tumors, HNSC head and neck squamous cell carcinoma, LAML acute myeloid leukemia, LCML chronic myelogenous leukemia, LIHC liver hepatocellular carcinoma, MATBCL mature B cell lymphoma, MB medulloblastoma, MEL melanoma, MEN meningioma, MESO mesothelioma, MGCT malignant giant cell tumor of bone, MM multiple myeloma, NSCLC non-small cell lung cancer, OVARIAN ovarian cancer, PAAD pancreatic adenocarcinoma, PNET primitive neuroectodermal tumors, PRAD prostate adenocarcinoma, RCC renal cell carcinoma, SAR sarcoma, SCLC small cell lung cancer, STAD stomach adenocarcinoma, THCA thyroid carcinoma, UCEC uterine corpus endometrial carcinoma, MISC other miscellaneous categories of cancer including rare cancers or cancers with unspecified information, Pan-cancer combined analysis of all cancer categories